Comparing Breast Magnetic Resonance Imaging (MRI) and Contrast-enhanced Mammography (CEM)

Sponsor
Boston Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06008301
Collaborator
Breast Cancer Alliance (Other)
60
2
23

Study Details

Study Description

Brief Summary

The investigators will study the financial, time, and psychologic benefit of Contrast Enhanced Mammography (CEM) compared with Magnetic Resonance Imaging (MRI) for breast cancer evaluation and ultimately encourage practices and referring providers to use it more routinely in practice.

Specific research objectives are to:
  • determine financial costs of performing a CEM to breast MRI

  • compare time costs involved with CEM to breast MRI

  • compare psychologic costs involved with CEM to breast MRI.

Condition or Disease Intervention/Treatment Phase
  • Other: State-Trait Anxiety Inventory (STAI)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Comparing Impact of Contrast-enhanced Mammography (CEM) to Breast MRI on Barriers to Breast Cancer Treatment
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Consent for the entire study

Participants with a newly diagnosed breast cancer and recommended for enhanced imaging will be randomly assigned to either CEM or MRI and take the State-Trait Anxiety Inventory (STAI) before and after imaging.

Other: State-Trait Anxiety Inventory (STAI)
The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.

Active Comparator: Consent only for the STAI

Participants with a newly diagnosed breast cancer and recommended for enhanced imaging but who cannot or choose not to be randomly assigned to CEM or MRI but they consent to take the State-Trait Anxiety Inventory (STAI) before and after imaging.

Other: State-Trait Anxiety Inventory (STAI)
The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.

Outcome Measures

Primary Outcome Measures

  1. Institutional financial costs [24 months]

    True institutional costs will be calculated using time-driven activity based costing (TDABC) methodology to estimate the capacity cost rate (CCR, defined as cost per unit time in dollars per minute for personnel, equipment, and fixed equipment) and total cost (TC, defined as the sum of CCR per resource multiplied by time utilization and added to cost of consumable materials) for MRI and CEM.

  2. Patient financial costs [24 months]

    Patient costs will be determined by capturing insurance coverage and hospital-provided patient charges.

  3. Time from diagnosis to imaging modality (CEM or MRI) [24 months]

    Time will be measured in days and abstracted from medical records.

  4. Time from diagnosis to first treatment [24 months]

    Time will be measured in days and abstracted from medical records.

  5. Number of patient visits generated from the imaging modality [24 months]

    Number of patient visits generated from the imaging modality will be abstracted from medical records.

  6. Psychologic costs to patients [24 months]

    The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > or equal to 30 years

  • Clinically eligible for CEM or breast MRI

  • Newly diagnosed cancer

Exclusion Criteria:
  • Pregnant as verified by patient report. Given that this test is being performed for clinical purposes, the determination of pregnancy status will be resolved via the standard clinical pathway.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Boston Medical Center
  • Breast Cancer Alliance

Investigators

  • Principal Investigator: Jordana Phillips, MD FSBI, Boston Medical Center, Dept of Radiology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Boston Medical Center
ClinicalTrials.gov Identifier:
NCT06008301
Other Study ID Numbers:
  • H-44009
First Posted:
Aug 23, 2023
Last Update Posted:
Aug 23, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Boston Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2023